title: Outcome of standardized treatment for patients with MDR-TB from Tamil Nadu, India.
abstract: OBJECTIVE
  Programmatic management of MDR-TB using a standardized treatment regimen (STR) is being implemented under the Revised National Tuberculosis Control Programme (RNTCP) in India. This study was undertaken to analyse the outcomes of MDR-TB patients treated at the Tuberculosis Research Centre, Chennai, with the RNTCP recommended 24 months STR, under programmatic conditions.
  
  
  METHODS
  Patients failed to the category II re-treatment regimen and confirmed to have MDR-TB, were treated with the RNTCP's STR in a prospective field trial on a predominantly ambulatory basis. Thirty eight patients were enrolled to the trial from June 2006 to September 2007.
  
  
  RESULTS
  Time to culture conversion was two months or less for 82 per cent of patients. Culture conversion rates at 3 and 6 months were 84 and 87 per cent respectively. At the end of treatment, 25 (66%) were cured, 5 defaulted, 3 died and 5 failed. At 24 months, 30 (79%) patients, including 5 defaulters, remained culture negative for more than 18 months. Twenty two (58%) patients reported adverse drug reactions (ADRs) which required dose reduction or termination of the offending drug. No patient had XDR-TB initially, but 2 failure cases emerged as XDR-TB during treatment.
  
  
  CONCLUSIONS
  Outcomes of this small group of MDR-TB patients treated with the RNTCP's STR is encouraging in this setting. Close attention needs to be paid to ensure adherence, and to the timely recognition and treatment of ADRs.
authors.affiliation: Tuberculosis Research Centre (ICMR), Chennai, India.
authors.forename: Pauline
authors.initials: P
authors.lastname: Joseph
authors.forename: Vijaya Bhaskara Rao
authors.initials: VB
authors.lastname: Desai
authors.forename: Nalini Sunder
authors.initials: NS
authors.lastname: Mohan
authors.forename: Jemima Sheila
authors.initials: JS
authors.lastname: Fredrick
authors.forename: Rajeswari
authors.initials: R
authors.lastname: Ramachandran
authors.forename: Balambal
authors.initials: B
authors.lastname: Raman
authors.forename: Fraser
authors.initials: F
authors.lastname: Wares
authors.forename: Ranjani
authors.initials: R
authors.lastname: Ramachandran
authors.forename: Aleyamma
authors.initials: A
authors.lastname: Thomas
mesh_terms: D000328:Adult; D000904:Antibiotics, Antitubercular / Q000627:therapeutic use*; D003140:Communicable Disease Control / Q000379:methods / Q000706:statistics & numerical data; D003523:Cycloserine / Q000627:therapeutic use; D023801:Directly Observed Therapy; D064420:Drug-Related Side Effects and Adverse Reactions / Q000473:pathology; D004977:Ethambutol / Q000627:therapeutic use; D005000:Ethionamide / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007194:India; D007612:Kanamycin / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D015242:Ofloxacin / Q000627:therapeutic use; D011446:Prospective Studies; D011718:Pyrazinamide / Q000627:therapeutic use; D013183:Sputum / Q000382:microbiology; D013997:Time Factors; D016896:Treatment Outcome; D018088:Tuberculosis, Multidrug-Resistant / Q000188:drug therapy*
chemical_list: D000904:Antibiotics, Antitubercular; D011718:Pyrazinamide; D007612:Kanamycin; D004977:Ethambutol; D003523:Cycloserine; D015242:Ofloxacin; D005000:Ethionamide